Kezar Life Sciences (KZR) investor relations material

Executive summary

• Entered into a Merger Agreement on March 30, 2026, with Aurinia Pharma U.S., offering $6.955 per share plus a contingent value right (CVR) per share, subject to closing conditions including a minimum tender and net cash threshold.

• Strategic review led to a 70% workforce reduction and asset sales, including the Sec61-based program to Enodia for $1M upfront and potential milestones up to $127M.

• If the merger is not completed, alternatives include dissolution and liquidation, with cash available for distribution to stockholders.

Financial highlights

• Net loss for Q1 2026 was $5.8M, a significant improvement from $16.6M in Q1 2025, driven by lower R&D and G&A expenses.

• Operating expenses dropped to $7.4M from $17.7M year-over-year, mainly due to reduced clinical and personnel costs.

• Cash and cash equivalents stood at $66.2M as of March 31, 2026.

• No product revenue; collaboration revenue recognized in prior periods from Everest Medicines.

Outlook and guidance

• Cash runway expected to cover at least 12 months from the reporting date.

• R&D and G&A expenses projected to remain flat or decrease for the remainder of 2026 due to program suspensions and reduced headcount.

• Future funding needs depend on merger completion and realization of cost reductions.